U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07503288) titled 'Genotype and Subtype Mapping of the Hepatitis C Virus' on March 25.
Brief Summary: Chronic hepatitis C virus (HCV) infection is the second leading cause of primary liver cancer worldwide and the leading cause in the United States. In 2020, an estimate 260,000 deaths were attributable to HCV globally, nearly 80,000 of which occurred in Europe, mainly due to complications such as cirrhosis or hepatocellular carcinoma (HCC).
The CARTO-VHC study is a retrospective, observational, multicenter study based on data and samples collected during routine care from 2023 to 2024. The study does not involve direct human participation. The study ...